How many insider trades does FilingIQ track for IMNM?

FilingIQ tracks 77 Form 4 insider transactions for IMNM (Immunome Inc.), covering filings from Oct 6, 2020 onwards. 13 of those were filed in the last 90 days.

Are IMNM insiders net buyers or net sellers?

Across the full Form 4 history for IMNM, 38 transactions (49%) were open-market purchases and 9 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IMNM insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IMNM in?

Immunome Inc. (IMNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.47B.

IMNM insider trading

NasdaqCM Healthcare

Immunome Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

49% / 12%

Market cap

$2.47B

About Immunome Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Company website: immunome.com

IMNM insider activity at a glance

FilingIQ has scored 77 insider transactions for IMNM since Oct 6, 2020. The most recent filing in our index is dated Apr 2, 2026.

Across the full history, 38 open-market purchases and 9 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IMNM insider trades is 55.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IMNM trades on FilingIQ Raw filings on SEC EDGAR

Latest IMNM Form 4 filings

SIEGALL CLAY B President and CEO

P Jan 31, 2025

SIEGALL CLAY B President and CEO

P Oct 2, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for IMNM?: FilingIQ tracks 77 Form 4 insider transactions for IMNM (Immunome Inc.), covering filings from Oct 6, 2020 onwards. 13 of those were filed in the last 90 days.
Are IMNM insiders net buyers or net sellers?: Across the full Form 4 history for IMNM, 38 transactions (49%) were open-market purchases and 9 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IMNM insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IMNM in?: Immunome Inc. (IMNM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.47B.

Methodology & sources

Every IMNM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.